CD99 Antibody IgG4 Composition for Inoperable Pediatric Solid Tumors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for aggressive brain tumors like DIPG, such as radiation and chemotherapy, are ineffective, and surgical resection is not possible due to the tumor's location, leading to a 0% survival rate, highlighting the urgent need for novel targeted therapies.
Innovation Solution
Development of a novel therapeutic CD99 antibody with specific CDR sequences (SEQ ID NOs: 6, 7, 8, 10, 11, 12) and an IgG4 Fc domain, designed to target the CD99 protein on cancer cells, combined with radiation therapy to enhance treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies (radiation and chemotherapy) are used to treat DIPG, then temporary tumor reduction may be achieved, but survival rate remains at 0% and treatment effectiveness is limited
Solution Approach 1:
The patent applies parameter changes by developing a novel antibody with specific CDR sequences (SEQ ID NOs: 6, 7, 8, 10, 11, 12) that fundamentally alter the binding parameters and mechanism of action compared to conventional therapies. This new antibody targets CD99 with high specificity, changing the therapeutic parameter from non-specific chemotherapy/radiation to highly specific targeted therapy, thereby improving both treatment effectiveness and survival outcomes
Solution Approach 2:
The patent employs composite materials by creating a chimeric antibody structure that combines variable regions with specific CDR sequences from one species with constant regions from another species (IgG4 Fc domain). This composite antibody structure integrates the specificity of targeted binding with the effector functions of the Fc region, enabling both tumor cell targeting and immune system activation, thus resolving the contradiction between temporary reduction and sustained survival benefit
2Reliability
If surgical resection is attempted for DIPG, then complete tumor removal might be achieved, but the procedure is not possible due to the tumor's location in the pons
Solution Approach 1:
The patent uses an intermediary approach by deploying a circulating antibody molecule as a mediator that can access the tumor through the bloodstream and cross the blood-brain barrier, thereby eliminating the need for direct surgical access to the inoperable tumor site in the pons. The antibody serves as the intermediary carrier that delivers the therapeutic effect without requiring physical surgical intervention
Solution Approach 2:
The patent replaces the mechanical surgical resection system with a biochemical antibody-based therapy system. Instead of using physical surgical instruments to mechanically remove the tumor, the invention uses biochemical molecules (antibodies) that selectively bind to and eliminate tumor cells through biological mechanisms, thus substituting the mechanical approach with a biochemical one that is suitable for inoperable tumors
3Reliability
If a therapeutic antibody is designed to target CD99 on cancer cells, then specific anti-tumor activity is achieved, but the complexity of antibody development and production increases
Solution Approach 1:
The patent applies segmentation by dividing the antibody into distinct functional segments: variable regions containing CDR sequences (SEQ ID NOs: 6, 7, 8, 10, 11, 12) that provide target-specific binding, and constant Fc regions that provide effector functions. This segmentation allows independent optimization of each segment - the CDRs for specificity and the Fc for immune activation - thereby achieving high targeted therapy specificity while managing structural complexity through modular design
Solution Approach 2:
The patent achieves universality by designing the antibody with an IgG4 Fc domain that provides multiple effector functions including complement activation, antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP). This multi-functional Fc region allows a single antibody molecule to engage multiple immune mechanisms simultaneously, thereby achieving comprehensive anti-tumor activity without requiring multiple different antibody molecules, thus managing complexity through functional consolidation
4Reliability
If combination therapy with radiation and CD99 antibody is implemented, then synergistic anti-tumor effect is achieved, but the treatment protocol complexity increases
Solution Approach 1:
The patent applies merging by combining radiation therapy and CD99 antibody therapy into a unified treatment protocol that exploits synergistic interactions between the two modalities. The antibody and radiation work together through complementary mechanisms - the antibody targets and sensitizes tumor cells while radiation delivers localized energy - creating a merged therapeutic approach that achieves greater anti-tumor efficacy than either modality alone, while the synergistic effect actually reduces the required dose of each individual treatment
Data Source
AI summary
Methods, compositions, and systems for treating various cancers are disclosed. The disclosed compositions may include a poly peptide with affinity for a CD99 cell surface protein. Disclosed polypeptides may comprise a sequence selected from GYYMH, RINPYTGATTYNQIFKD, YYYGNNYNVYLDY, SASQGISNYLS, YTSTLHIS, and QQYSNLPWT, and may include mouse, human, or humanized peptide sequences. In many embodiments, the polypeptides may be immunoglobulins, for example IgG3 or IgG4. The disclosed polypeptides may be administered to a subject having a cancer cell with elevated expression of CD99. In some embodiments, the subject may be suffering from cancer, including diffuse intrinsic pontine glioma (DIPG). Ewing Sarcoma, acute myeloid leukemia (AML), ependymoma, or neuroblastoma. Treatment methods include administering the disclosed polypeptides to a subject that may also be treated with radiation. Disclosed herein are systems for treating one or more cancers. The systems may comprise a radiation source, for example a medical fractionated radiation source.